Health Catalyst, Inc Common Stock (HCAT) is a publicly traded Healthcare sector company. As of May 21, 2026, HCAT trades at $1.29 with a market cap of $93.85M and a P/E ratio of -0.34. HCAT moved +2.36% today. Year to date, HCAT is -43.67%; over the trailing twelve months it is -67.26%. Its 52-week range spans $0.96 to $9.24. Analyst consensus is neutral with an average price target of $2.11. Rallies surfaces HCAT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Health Catalyst Q1 Revenue Drops 11% to $70.8M as Adjusted EBITDA Jumps 46%: Health Catalyst’s first-quarter revenue declined 11% year-over-year to $70.8 million while GAAP net loss widened to $111.0 million as the company pursued a strategic operating-model reset. Adjusted EBITDA rose 46% to $9.1 million and adjusted gross margin expanded two points to 51%.
| Metric | Value |
|---|---|
| Price | $1.29 |
| Market Cap | $93.85M |
| P/E Ratio | -0.34 |
| EPS | $-3.74 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.24 |
| 52-Week Low | $0.96 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $302.48M |
| Net Income | $-265.26M |
| Gross Margin | 0.00% |
9 analysts cover HCAT: 0 strong buy, 2 buy, 7 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $2.11.